UK markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.9700+0.0800 (+2.06%)
At close: 04:00PM EDT
3.9800 +0.01 (+0.25%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.8900
Open3.8900
Bid3.9700 x 1800
Ask4.0000 x 1800
Day's range3.8600 - 4.0199
52-week range3.5300 - 11.3600
Volume2,900,400
Avg. volume7,432,624
Market cap555.613M
Beta (5Y monthly)1.60
PE ratio (TTM)N/A
EPS (TTM)-5.4100
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.40
  • Insider Monkey

    12 Most Shorted Stocks in 2024

    In this article, we will take a detailed look at the 12 Most Shorted Stocks in 2024. For a quick overview of such stocks, read our article 5 Most Shorted Stocks in 2024. Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that […]

  • GlobeNewswire

    Shah Capital nominates two highly qualified independent director candidates for Novavax

    Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outd

  • Reuters

    UPDATE 4-Novavax investor Shah Capital pushes for board shakeup

    Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.